Novel treatment options for acute myelocytic leukemia
Michael S. Mathisen, Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Elias Joseph Jabbour · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
Acute myelocytic leukemia (AML) is an extremely heterogeneous disease with outcomes that vary widely according to subtype of the disease. Nevertheless, the majority of patients are not cured of the disease, and improvements in therapy are required. A number of recent studies challenge the notion that ‘7 + 3’ chemotherapy (cytarabine combined with an anthracycline) is the standard of care for most patients with AML. Targeted therapy with monoclonal antibodies and small-molecule kinase inhibitors are very promising strategies to help improve the cure rate. This review will highlight the results of recent clinical trials in which outcomes have been influenced significantly.
Novel approaches to sequencing and combining available therapies will also be covered. Finally, molecularly targeted therapies relevant to AML will be discussed.
Open the resolved locator · 10.4155/cli.13.78
Metadata licence: OpenAlex metadata (CC0)